suizenji + gemcitabine + nab-paclitaxel

A combination therapy consisting of **suizenji**, **gemcitabine**, and **nab-paclitaxel**. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis, primarily used as a chemotherapy agent for pancreatic and other cancers. - **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of paclitaxel, which inhibits cell division by stabilizing microtubules; it is used as a chemotherapeutic for various cancers, most notably pancreatic cancer in combination with gemcitabine[1][2][7]. - **Suizenji** does not correspond to a known pharmaceutical or biologic in the context of standard chemotherapies, targeted agents, or dietary supplements, and there is no evidence for its use in combination with gemcitabine and nab-paclitaxel in oncology or other indications found in current scientific or regulatory sources as of the specified date. Gemcitabine plus nab-paclitaxel is FDA-approved and commonly used for metastatic pancreatic cancer due to improved overall and progression-free survival compared to gemcitabine alone. Administration is intravenous, and common side effects include neutropenia, neuropathy, and fatigue[1][2][6][7].